Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures
Open Access
- 23 August 2005
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 93 (5) , 504-509
- https://doi.org/10.1038/sj.bjc.6602750
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Vioxx, the implosion of Merck, and aftershocks at the FDAThe Lancet, 2004
- Accelerated Approval of Oncology Products: A Decade of ExperienceJNCI Journal of the National Cancer Institute, 2004
- Beyond Fast Track for Drug ApprovalsNew England Journal of Medicine, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Efficacy, safety, and cost of new anticancer drugsBMJ, 2002
- Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical TrialsJournal of Clinical Oncology, 2002
- Patient-Reported Outcomes: The Example of Health-Related Quality of Life—a European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory ProcessDrug Information Journal, 2002
- The decline in cancer mortality in the European Union, 1988–1996European Journal Of Cancer, 2000
- The EUROCARE II studyEuropean Journal Of Cancer, 1998